Held by 3 specialist biotech funds
High Convergence# Signal Note: Rock Springs Capital Initiates $37.5M Penumbra Position Rock Springs' entry into PEN suggests conviction in the company's neurointerventional device portfolio, likely driven by upcoming clinical data or reimbursement milestones for its ischemic stroke and hemorrhagic stroke platforms.
AI analyst context — unlock full analysis
# Signal Note: RTW Investments Initiates $269M Position in Penumbra (PEN) Wong's data-driven team is betting on Penumbra's neurointerventional and aspiration thrombectomy platforms, likely motivated by strong Q3 revenue growth (26% YoY) and expanding TAM in acute ischemic stroke treatment. The $269M stake signals confidence in sustained margin expansion and international market penetration, particularly in the high-growth EMEA region where Penumbra has accelerated adoption.
+ 1more — see how much conviction went in
See the Full Story